Literature DB >> 10908271

Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension.

D Abrams1, I Schulze-Neick, A G Magee.   

Abstract

Primary pulmonary hypertension is a rare disease of childhood, which carries a poor prognosis. Patients often present with severe exercise limitation, and untreated life expectancy is less than 1 year. Pharmacological intervention is directed towards reduction of the raised pulmonary artery pressure with vasodilator treatment, initially with calcium antagonists, although more recently long term prostacyclin treatment has shown benefit in some patients. Heart-lung transplantation remains an option for children with severe disease refractory to therapeutic treatment. A 4 year old Bangladeshi girl with dyspnoea, cyanosis, and signs of a low cardiac output, is described. Initial treatment with prostacyclin was gradually reduced, and maintenance treatment with oral sildenafil (Viagra; Pfizer) instituted. At follow up 3 months later, her exercise capacity was greatly improved and she continues to enjoy a good quality of life without obvious side effects. In view of the encouraging initial results, this may become an acceptable adjunct in treating this patient group.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10908271      PMCID: PMC1760898          DOI: 10.1136/heart.84.2.e4

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  8 in total

1.  Sildenafil ameliorates effects of inhaled nitric oxide withdrawal.

Authors:  A M Atz; D L Wessel
Journal:  Anesthesiology       Date:  1999-07       Impact factor: 7.892

2.  The Registry of the International Society of Heart and Lung Transplantation: first official pediatric report--1997.

Authors:  M M Boucek; R J Novick; L E Bennett; B Fiol; B M Keck; J D Hosenpud
Journal:  J Heart Lung Transplant       Date:  1997-12       Impact factor: 10.247

3.  Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds.

Authors:  I V Turko; S A Ballard; S H Francis; J D Corbin
Journal:  Mol Pharmacol       Date:  1999-07       Impact factor: 4.436

4.  Cyclic-GMP-binding, cyclic-GMP-specific phosphodiesterase (PDE5) gene expression is regulated during rat pulmonary development.

Authors:  L S Sanchez; S M de la Monte; G Filippov; R C Jones; W M Zapol; K D Bloch
Journal:  Pediatr Res       Date:  1998-02       Impact factor: 3.756

5.  Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.

Authors:  V V McLaughlin; D E Genthner; M M Panella; S Rich
Journal:  N Engl J Med       Date:  1998-01-29       Impact factor: 91.245

6.  Vasodilator therapy for primary pulmonary hypertension in children.

Authors:  R J Barst; G Maislin; A P Fishman
Journal:  Circulation       Date:  1999-03-09       Impact factor: 29.690

7.  Pediatric heart-lung transplantation: intermediate-term results.

Authors:  J V Conte; R C Robbins; H Reichenspurner; V G Valentine; J Theodore; B A Reitz
Journal:  J Heart Lung Transplant       Date:  1996-07       Impact factor: 10.247

8.  A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.

Authors:  R J Barst; L J Rubin; W A Long; M D McGoon; S Rich; D B Badesch; B M Groves; V F Tapson; R C Bourge; B H Brundage; S K Koerner; D Langleben; C A Keller; S Murali; B F Uretsky; L M Clayton; M M Jöbsis; S D Blackburn; D Shortino; J W Crow
Journal:  N Engl J Med       Date:  1996-02-01       Impact factor: 91.245

  8 in total
  33 in total

Review 1.  Sildenafil for pulmonary hypertension in neonates.

Authors:  Lauren E Kelly; Arne Ohlsson; Prakeshkumar S Shah
Journal:  Cochrane Database Syst Rev       Date:  2017-08-04

2.  Severe retinopathy of prematurity (ROP) in a premature baby treated with sildenafil acetate (Viagra) for pulmonary hypertension.

Authors:  C S Marsh; B Marden; R Newsom
Journal:  Br J Ophthalmol       Date:  2004-02       Impact factor: 4.638

3.  Sildenafil Use in Children with Pulmonary Hypertension.

Authors:  Jennifer L Cohen; Shannon N Nees; Gerson A Valencia; Erika B Rosenzweig; Usha S Krishnan
Journal:  J Pediatr       Date:  2018-11-02       Impact factor: 4.406

4.  Is sildenafil effective in secondary pulmonary hypertension due to systemic lupus erythematosus? A case report.

Authors:  Ismail Hanta; Mesut Demir; Onur Akpinar; Ali Kocabas; Suleyman Ozbek
Journal:  Clin Rheumatol       Date:  2005-06-11       Impact factor: 2.980

5.  [Recommendations of the German Society of Rheumatology on therapy of pulmonary hypertension in patients with autoimmune diseases].

Authors:  H Schulze-Koops
Journal:  Z Rheumatol       Date:  2005-03       Impact factor: 1.372

Review 6.  [Medicinal vasoactive therapy of microcirculation disorders in rheumatoid arthritis].

Authors:  G Riemekasten; H Schulze-Koops
Journal:  Z Rheumatol       Date:  2005-03       Impact factor: 1.372

7.  Sildenafil--a possible treatment for acute pulmonary hypertension during cardiac surgery.

Authors:  Wendy Wheeler; Shelly Hayes; Ngo Nguyen; Anthony M Cilla; Joseph Rybowicz; Comeco C Jones; Michael A E Ramsay; Shelley A Hall; Dan Meyer; John Capehart; Michael E Jessen; Steves Ring
Journal:  Proc (Bayl Univ Med Cent)       Date:  2002-01

Review 8.  Therapeutic applications of sildenafil citrate in the management of paediatric pulmonary hypertension.

Authors:  Leah Leibovitch; Ilan Matok; Gideon Paret
Journal:  Drugs       Date:  2007       Impact factor: 9.546

9.  Sildenafil therapy for pulmonary hypertension before and after pediatric congenital heart surgery.

Authors:  Gaetano Palma; Raffaele Giordano; Veronica Russolillo; Sabato Cioffi; Sergio Palumbo; Marco Mucerino; Vincenzo Poli; Carlo Vosa
Journal:  Tex Heart Inst J       Date:  2011

10.  Sildenafil reduces insulin-resistance in human endothelial cells.

Authors:  Caterina Mammi; Donatella Pastore; Marco F Lombardo; Francesca Ferrelli; Massimiliano Caprio; Claudia Consoli; Manfredi Tesauro; Lucia Gatta; Massimo Fini; Massimo Federici; Paolo Sbraccia; Giulia Donadel; Alfonso Bellia; Giuseppe M Rosano; Andrea Fabbri; Davide Lauro
Journal:  PLoS One       Date:  2011-01-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.